Full Thickness Macular Hole and Internal Limiting Membrane Peeling Study (FILMS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00286507 |
Recruitment Status :
Completed
First Posted : February 3, 2006
Last Update Posted : June 6, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Stage 2 or 3 Full Thickness Macular Hole | Procedure: Vitrectomy, post hyaloid detachment and gas injection with or without ILM peel. | Not Applicable |
Idiopathic full-thickness macular hole (FTMH) is an important cause of loss of central vision, usually leading to severe visual impairment. Up to 20% of affected people will develop a FTMH in both eyes. There is uncertainty in the literature and among vitreo-retinal surgeons about the balance of potential benefits and adverse effects of ILM peeling in FTMH surgery for stage 2-3 holes.
FILMS is a randomised controlled trial (RCT) in patients with stage 2-3 FTMH less less than 18 months duration investigating whether ILM peeling improves the anatomical and visual outcome of macular hole surgery and the quality of life of patients with this retinal disease. Cost-effectiveness is also being addressed.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 141 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Participant) |
Primary Purpose: | Treatment |
Official Title: | Full Thickness Macular Hole and Internal Limiting Membrane Peeling Study: Randomised Comparison of Macular Hole Surgery With or Without Internal Limiting Membrane Peeling |
Study Start Date : | July 2005 |
Actual Primary Completion Date : | September 2009 |
Actual Study Completion Date : | September 2011 |
Arm | Intervention/treatment |
---|---|
Active Comparator: ILM peeling
Combined cataract surgery (phacoemulsification and intraocular lens implantation) and pars plana vitrectomy with postoperative intraocular tamponade with gas, with ILM peeling
|
Procedure: Vitrectomy, post hyaloid detachment and gas injection with or without ILM peel.
Combined cataract surgery (phacoemulsification and intraocular lens implantation) and pars plana vitrectomy with postoperative intraocular tamponade with gas, with or without ILM peeling |
Active Comparator: No ILM peeling
combined cataract surgery (phacoemulsification and intraocular lens implantation) and pars plana vitrectomy with postoperative intraocular tamponade with gas without ILM peeling
|
Procedure: Vitrectomy, post hyaloid detachment and gas injection with or without ILM peel.
Combined cataract surgery (phacoemulsification and intraocular lens implantation) and pars plana vitrectomy with postoperative intraocular tamponade with gas, with or without ILM peeling |
- The primary outcome of the study is the mean difference between treatment groups in the Early Treatment Diabetic Retinopathy Study (ETDRS) distance visual acuity score. [ Time Frame: 6 months post surgery ]
- Secondary outcomes include anatomical closure, adverse events, re-operation, distance visual acuity (VA), near VA, contrast sensitivity, reading speed, costs to the health service and the participant and HRQOL. [ Time Frame: 3, 6 and 24 months post surgery ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Idiopathic FTMH of stage 2-3, Duration of hole ≤18 months, Visual acuity equal to or worse than 20/40 in the study eye.
Exclusion Criteria:
Stage 1 or 4 FTMH, Stage 2-3 FTMH of > 18 months duration, Visual acuity >20/40 in study eye, FTMH related to high myopia (>6 dioptres), FTMH related to trauma, any other causes of decreased vision (ie corneal scarring, age-related macular degeneration, diabetic retinopathy, glaucoma if central and/or paracentral absolute visual field defects present), patient unable to understand English, patient unable to give informed consent.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00286507
Ireland | |
Royal Victoria Eye and Ear Hospital | |
Dublin, Ireland | |
Waterford Regional Hospital | |
Waterford, Ireland | |
United Kingdom | |
Aberdeen Royal Infirmary | |
Aberdeen, United Kingdom | |
Bristol Eye Hospital | |
Bristol, United Kingdom | |
Ninewells Hospital | |
Dundee, United Kingdom | |
Gartnavel General Hospital | |
Glasgow, United Kingdom | |
Royal Liverpool Hospital | |
Liverpool, United Kingdom | |
Oxford Eye Hospital | |
Oxford, United Kingdom | |
Sunderland Eye Infirmary | |
Sunderland, United Kingdom |
Principal Investigator: | Noemi Lois | NHS Grampian |
Responsible Party: | University of Aberdeen |
ClinicalTrials.gov Identifier: | NCT00286507 |
Other Study ID Numbers: |
CZH/4/235 |
First Posted: | February 3, 2006 Key Record Dates |
Last Update Posted: | June 6, 2012 |
Last Verified: | June 2012 |
Full thickness macular hole Internal limiting membrane (ILM) Vitreo retinal surgery Vitrectomy |
Retinal Perforations Retinal Diseases Eye Diseases |